Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company focused on advancing precision nerve-targeted treatments, recently participated in a Virtual Investor CEO Connect segment. During the event, CEO Brad Hauser highlighted the company's commitment to expanding its intellectual property portfolio and exploring multi-indication opportunities for its platform technology, which includes a catheter-based microchip sensing array aimed at improving the diagnosis and treatment of diseases involving the nervous system. Hauser discussed the company's initial focus on pain management, particularly in pancreatic cancer, and emphasized potential future applications in cardiovascular, pulmonary, and interventional pain management. The Virtual Investor CEO Connect segment is now available here.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9616285-en) on December 23, 2025, and is solely responsible for the information contained therein.